Multigene germline testing for epithelial ovarian cancer in China
Cancer · 01.05.2026 · 132 (9)
DOI: 10.1002/cncr.70395 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer, online erschienen am 26.04.2026. Verfasst von Lei Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China. Hauptthemen laut MEDLINE: Carcinoma, Ovarian Epithelial, Germ-Line Mutation, Ovarian Neoplasms, Genetic Testing. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Key Research Project of Beijing Natural Science Foundation, Independent Research Fund of State Key Laboratory of Complex, Severe and Rare Diseases in Peking Union Medical College Hospital, National Key Clinical Specialty Construction Project.
Abstract (Originalsprache)
Background
Large‐scale studies of germline variants in hereditary cancer susceptibility genes among Chinese epithelial ovarian cancer (EOC) patients remain limited. This study assessed the prevalence and clinical significance of germline variants in 21 genes relevant to hereditary breast and ovarian cancer.
Methods
In this multicenter prospective cohort (February 2017–December 2018), 961 unselected EOC patients underwent germline testing for 21 genes. Variant frequencies were compared with international data, and associations with clinicopathologic characteristics and survival outcomes were evaluated.
Results
Pathogenic or likely pathogenic (P/LP) variants were identified in BRCA1 (17.79%), BRCA2 (6.35%), and other homologous recombination (HR)‐related genes (2.71%). P/LP variants in non‐HR‐related genes were rare (0.1%). BRCA1 and BRCA1/2 P/LP variant carriers were more likely to respond to platinum‐based chemotherapy ( p = .002 and p < .001). Variants of uncertain significance or higher (VUS+) in HR‐related genes were associated with better overall survival (hazard ratio, 0.57; p = 0.004) and progression‐free survival (hazard ratio, 0.75; p = 0.02), with a trend more pronounced than that observed for BRCA1/2 VUS + carriers.
Conclusions
Over 25% of Chinese EOC patients carry germline HR‐related gene variants, which are associated with better treatment response and survival. Broad genetic testing is critical, and the prognostic value of VUS warrants further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China.
- National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, China.
- State Key Laboratory for Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, China.
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gynecology, Peking University Cancer Hospital & Institute, Beijing, China.
- Department of Gynecology Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong Province, China.
- Gynecology Oncology Center, People's Hospital, Peking University, Beijing, China.
Förderung
- Key Research Project of Beijing Natural Science Foundation
- Independent Research Fund of State Key Laboratory of Complex, Severe and Rare Diseases in Peking Union Medical College Hospital
- National Key Clinical Specialty Construction Project
- Peking Union Medical College Hospital Talent Cultivation Program
- National High Level Hospital Clinical Research Funding
- CAMS Innovation Fund for Medical Sciences
- Beijing Key Clinical Specialty Project
Zitieren
APA
Li, L., Song, N., Zhang, D., Li, Y., Rao, Y., Liu, C., Qiao, Z., Zhang, J., Shao, K., Wu, M., & ECO‐GENE study group (2026). Multigene germline testing for epithelial ovarian cancer in China. Cancer, 132(9). https://doi.org/10.1002/cncr.70395
Vancouver
Li L, Song N, Zhang D, Li Y, Rao Y, Liu C, et al. Multigene germline testing for epithelial ovarian cancer in China. Cancer. 2026;132(9). doi:10.1002/cncr.70395
BibTeX
@article{Li2026,
author = {Li, Lei and Song, Nan and Zhang, Depu and Li, Yi and Rao, Yang and Liu, Chunyan and Qiao, Zhiwei and Zhang, Jianwei and Shao, Kang and Wu, Ming and ECO‐GENE study group, ECO‐GENE study group},
title = {Multigene germline testing for epithelial ovarian cancer in China},
journal = {Cancer},
year = {2026},
volume = {132},
number = {9},
doi = {10.1002/cncr.70395}
}
EUVIMED